Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.54 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | DBH | P09172 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480603 | 0.84 | KMT2A (0.58) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C | |
| SCHEMBL3685675 | 0.84 | KDM4E (0.50) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C | |
| SCHEMBL9559796 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C | |
| SCHEMBL10730260 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C | |
| SCHEMBL16868406 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C | |
| SCHEMBL19520440 | 0.83 | ALDH1A1 (0.55) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C | |
| SCHEMBL9666038 | 0.83 | PLK1 (0.56) | ALDH1A1PLK1TAS1R3TAS1R1KDM4E | |
| SCHEMBL10121174 | 0.83 | KDM4E (0.62) | ALDH1A1ADRA2BKCNH2KDM4EDBH | |
| SCHEMBL12158530 | 0.83 | SLC6A2 (0.49) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C | |
| SCHEMBL9617195 | 0.82 | CHRM2 (0.58) | ALDH1A1CHRM2CYP2D6ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0000285-B1 | 7-ACYLAMINO-3-((3-(CARBOXYMETHYL) THIO-1 H-1,2,4-TRIAZOL-5-YL) THIOMETHYL)-3-CEPHEM-4-CARBOXYLIC ACID DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1982-02-17 | — | — | EP | claimed |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-25 | — | — | US | disclosed |
| US-11576890-B2 | Purified forms of rofecoxib, methods of manufacture and use | Tremeau Pharmaceuticals, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-11572364-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-02-07 | — | — | US | disclosed |
| US-20210236455-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | Tremeau Pharmaceuticals, Inc. (US) | 2021-08-05 | — | — | US | disclosed |
| EP-3789426-A1 | POLYARYLETHER KETONE IMIDE SULFONE ADHESIVES | The Boeing Company (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20170290928-A1 | USE OF CHARGE-BALANCED IMAGING AGENTS FOR DETERMINING RENAL FUNCTION | BETH ISRAEL DEACONESS MEDICAL CT INC (US) | 2017-10-12 | — | — | US | disclosed |
| EP-0414207-B1 | Method for preparing alpha-(-4-isobutylphenyl) propionic acid or its precursor | NIPPON PETROCHEMICALS CO LTD (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0373362-B1 | METHOD FOR PREPARING P-ISOBUTYLSTYRENE | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1993-02-03 | — | — | EP | disclosed |
| US-5166419-A | Multistage reaction by catalytic dehydrogenation and reaction with carbon monoxide | NIPPON PETROCHEMICALS CO., LTD. (JP) | 1992-11-24 | — | — | US | disclosed |
| EP-0273647-B1 | COUMARAN DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-03-11 | — | — | EP | disclosed |
| EP-0423524-A2 | Propiophenone derivatives and their preparation and pharmaceutical use | MARUHO Co., Ltd. (JP) | 1991-04-24 | — | — | EP | disclosed |
| EP-0414207-A2 | Method for preparing alpha-(-4-isobutylphenyl) propionic acid or its precursor | NIPPON PETROCHEMICALS CO., LTD. (JP) | 1991-02-27 | — | — | EP | disclosed |
| EP-0373362-A1 | Method for preparing p-isobutylstyrene | NIPPON PETROCHEMICALS COMPANY, LIMITED (JP) | 1990-06-20 | — | — | EP | disclosed |
| US-4857516-A | Coumaran derivatives and their pharmaceutical use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0273647-A1 | Coumaran derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-07-06 | — | — | EP | disclosed |
| US-4352748-A | Novel acyl-polyalkylindan compounds and the use thereof as a base for perfume, as well as perfume compositions | NAARDEN INTERNATIONAL N.V. (NL) | 1982-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236455-A1 | PURIFIED FORMS OF ROFECOXIB, METHODS OF MANUFACTURE AND USE | ITGA2B, F13B, F11 | ALDH1A1 2666/4885CHRM2 1668/4885CYP2D6 576/4885 |
| US-11872206-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | ALDH1A1 2666/4885CHRM2 1668/4885CYP2D6 576/4885 |
| US-11572364-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | ALDH1A1 569/4885CHRM2 4314/4885CYP2D6 1271/4885 |
| US-20230159569-A1 | DUAL HDAC6/PROTEASOME INHIBITORS, AND METHODS OF USE THEREOF | HDAC6, PSMG3, PSMB2 | ALDH1A1 2269/4885CHRM2 4843/4885CYP2D6 4748/4885 |
| US-11576890-B2 | Purified forms of rofecoxib, methods of manufacture and use | ITGA2B, F13B, F11 | ALDH1A1 2666/4885CHRM2 1668/4885CYP2D6 576/4885 |
| US-20180148453-A1 | DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, PDE4D | ALDH1A1 635/4885CHRM2 543/4885CYP2D6 584/4885 |
| US-20170290928-A1 | USE OF CHARGE-BALANCED IMAGING AGENTS FOR DETERMINING RENAL FUNCTION | ATP6V1B1, SLC8B1, PHOSPHO1 | ALDH1A1 4754/4885CHRM2 2723/4885CYP2D6 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.